IP Library Assignment 038180/0021
Patent Assignment
Reel/Frame 038180/0021

Security Agreement

Recorded: 2016-03-21 Pages: 17
Assignor
OREXIGEN THERAPEUTICS, INC.
Executed: 2016-03-21
Assignee
U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
60 LIVINGSTON AVENUE, ST. PAUL, MINNESOTA, 55107
Covered Properties (43)
Zonisamide use in obesity and eating disorders
Application: 10/429,474 →
Publication: US 2004/0029941
Compositions for Affecting Weight Loss
Patent: 7,375,111 →
Application: 10/828,795 →
Publication: US 2004/0254208
Zonisamide use in eating disorders
Application: 10/932,047 →
Publication: US 2005/0026977
Compositions of an Anticonvulsant and an Antipsychotic Drug and Methods of Using the Same for Affecting Weight Loss
Patent: 7,429,580 →
Application: 11/034,316 →
Publication: US 2005/0181070
Method for treating obesity
Application: 11/059,021 →
Publication: US 2005/0215552
Compositions for affecting weight loss
Application: 11/109,027 →
Publication: US 2006/0100205
Combination of bupropion and a second compound for affecting weight loss
Application: 11/194,201 →
Publication: US 2006/0058293
Compositions for Affecting Weight Loss
Patent: 7,462,626 →
Application: 11/356,839 →
Publication: US 2006/0142290
Methods and Compositions for Managing Psychotic Disorders
Application: 11/420,385 →
Publication: US 2006/0276412
Compositions for affecting weight loss
Application: 11/492,685 →
Publication: US 2007/0117827
Sustained-Release Formulation of Zonisamide
Application: 11/563,618 →
Publication: US 2007/0148237
Methods of Treating Anxiety Disorders
Application: 11/563,631 →
Publication: US 2007/0179168
Compositions and methods for increasing insulin sensitivity
Patent: 8,815,889 →
Application: 11/602,571 →
Publication: US 2007/0128298
Compositions and methods for reducing food cravings
Application: 11/602,813 →
Publication: US 2007/0129283
Compositions of an Anticonvulsant and Methods of Using the Same for Reversing Weight Gain
Application: 11/622,363 →
Publication: US 2007/0185084
Sustained Release Formulation of Naltrexone
Patent: 8,916,195 →
Application: 11/757,773 →
Publication: US 2007/0281021
Methods for Administering Weight Loss Medications
Application: 11/937,367 →
Publication: US 2008/0110792
Layered Pharmaceutical Formulations
Patent: 8,088,786 →
Application: 11/937,421 →
Publication: US 2008/0113026
Methods for Administering Weight Loss Medications
Patent: 8,722,085 →
Application: 12/838,364 →
Publication: US 2011/0059170
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Patent: 9,248,123 →
Application: 12/987,909 →
Publication: US 2011/0172260
Methods for Treating Visceral Fat Conditions
Application: 12/995,121 →
Publication: US 2011/0144145
Layered Pharmaceutical Formulations
Patent: 8,318,788 →
Application: 13/330,395 →
Publication: US 2012/0093889
Layered Pharmaceutical Formulations
Application: 13/680,922 →
Publication: US 2013/0177602
Methods for Reducing Binge or Compulsive Eating
Application: 13/991,372 →
Publication: US 2013/0252995
Compositions and Methods for Reducing Food Cravings
Application: 14/207,077 →
Publication: US 2014/0309252
Methods for Administering Weight Loss Medications
Patent: 9,125,868 →
Application: 14/220,349 →
Publication: US 2014/0322318
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 8,969,371 →
Application: 14/322,810 →
Compositions and Methods for Increasing Insulin Sensitivity
Patent: 9,457,005 →
Application: 14/326,075 →
Publication: US 2014/0323399
Methods of Treating Overweight and Obesity
Patent: 9,633,575 →
Application: 14/405,775 →
Publication: US 2015/0154883
Method for Treating Obesity
Application: 14/464,622 →
Publication: US 2014/0364468
Layered Pharmaceutical Formulations
Application: 14/541,525 →
Publication: US 2015/0164806
Sustained Release Formulation of Naltrexone
Patent: 9,107,837 →
Application: 14/555,475 →
Publication: US 2015/0080424
Methods for Treating Visceral Fat Conditions
Application: 14/584,985 →
Publication: US 2015/0119417
Compositions for Affecting Weight Loss
Application: 14/602,154 →
Publication: US 2015/0141452
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 9,119,850 →
Application: 14/635,518 →
Publication: US 2015/0182524
Method for Treating Obesity
Application: 14/663,338 →
Publication: US 2015/0320726
Sustained Release Formulation of Naltrexone
Application: 14/826,086 →
Publication: US 2016/0158221
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 9,801,875 →
Application: 14/839,792 →
Publication: US 2015/0366860
Methods for Administering Weight Loss Medications
Application: 14/844,476 →
Publication: US 2016/0193152
Layered Pharmaceutical Formulations
Application: 14/988,556 →
Publication: US 2016/0338965
Methods for Prophylatic Appetite Suppression
Application: 15/004,269 →
Publication: US 2016/0354348
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Application: 15/011,120 →
Publication: US 2016/0143903
Sustained Release Formulation of Naltrexone
Application: 15/046,373 →
Publication: US 2016/0158225
Related Assignments (8)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Mar 18, 2014
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 032463/0479 →
Assignment of Assignor's Interest Dec 18, 2015
From: DUNAYEVICH, EDUARDO; DEWITT (LEGAL REPRESENTATIVE OF GARY TOLLEFSON (DECEASED)), DAVID
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 037334/0490 →
Assignment of Assignor's Interest Mar 22, 2017
From: WEBER, ECKARD; COWLEY, MICHAEL ALEXANDER
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0847 →
Assignment of Assignor's Interest Aug 2, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 046688/0661 →
Security Interest Aug 6, 2018
From: NALPROPION PHARMACEUTICALS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 047288/0321 →
Release of Security Interest Sep 27, 2019
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 050574/0106 →
Change of Name Oct 17, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: NALPROPION PHARMACEUTICALS LLC
Reel/Frame 050750/0497 →
Security Interest Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →